Bayer, Amgen back ReCode’s plan to broaden genetic medicine’s reach

The two drugmakers joined a long list of investors, including Pfizer and Sanofi, that have been funding the startup’s plan to develop a new type of lipid nanoparticle technology. 

Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.


*